Tango Therapeutics

64 articles about Tango Therapeutics

• Tango Therapeutics to Highlight Preclinical Data on Precision Oncology Pipeline at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

  9/18/2023

  Tango Therapeutics, Inc. today announced that five abstracts have been selected for poster presentations at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, taking place from October 11-15, 2023 in Boston, Massachusetts.

• Tango Therapeutics to Participate in the H.C. Wainwright 25th Annual Global Investment Conference

  9/5/2023

  Tango Therapeutics, Inc. announced that Barbara Weber, M.D., President and Chief Executive Officer of Tango Therapeutics, is scheduled to participate in the H.C. Wainwright 25th Annual Global Investment Conference on Monday, September 11, 2023 at 4:00 PM ET.

• Tango Therapeutics Announces Updates to Its Board of Directors - August 29, 2023

  8/29/2023

  Tango Therapeutics, Inc., a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, announced changes to its Board of Directors.

• Tango Therapeutics Announces $80 million Private Placement Financing

  8/10/2023

  Tango Therapeutics, Inc. has agreed to sell approximately 15.5 million shares of its common stock in lieu thereof) to a select group of institutional and accredited healthcare specialist investors in a private investment in public equity financing, at a per share price of $5.15.

• Tango Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Highlights

  8/7/2023

  Tango Therapeutics, Inc., a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, reported its financial results for the second quarter ended June 30, 2023, and provided business highlights.

• Tango Therapeutics Announces First Patient Dosed in TNG260 Phase 1/2 Trial in Patients With STK11-Mutant Cancers

  7/24/2023

  Tango Therapeutics, Inc. today announced that the first patient has been dosed in the phase 1/2 trial evaluating TNG260 in combination with pembrolizumab in patients with STK11-mutant cancers.

• Tango Therapeutics Announces First Patient Dosed in TNG462 Phase 1/2 Trial in Patients With MTAP-deleted Solid Tumors

  7/10/2023

  Tango Therapeutics, Inc. today announced that the first patient has been dosed in the phase 1/2 trial of TNG462 in patients with MTAP-deleted solid tumors. TNG462 is a potentially best-in-class MTA-cooperative PRMT5 inhibitor previously granted Fast Track designation by the U.S. Food and Drug Administration.

• Tango Therapeutics to Participate in Upcoming June 2023 Investor Conferences

  6/1/2023

  Tango Therapeutics, Inc. announced that members of the management team are scheduled to participate in the following upcoming investor conferences in June.

• Tango Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Highlights

  5/9/2023

  Tango Therapeutics, Inc., a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, reported its financial results for the first quarter ended March 31, 2023, and provided business highlights.

• Tango Therapeutics Presents Preclinical Data on Precision Oncology Programs at the American Association of Cancer Research 2023 Annual Meeting

  4/18/2023

  Tango Therapeutics, Inc. (NASDAQ: TNGX) today announced highlights from presentations at the American Association for Cancer Research (AACR) 2023 Annual Meeting, taking place from April 14-19, 2023 in Orlando, Florida.

• Tango Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Highlights

  3/27/2023

  Tango Therapeutics, Inc. reported its financial results for the fourth quarter and full year ended December 31, 2022, and provided business highlights.

• Tango Therapeutics to Highlight Preclinical Data on Precision Oncology Programs at the American Association of Cancer Research 2023 Annual Meeting

  3/15/2023

  Tango Therapeutics, Inc. announced the acceptance of two oral and two poster presentations at the American Association for Cancer Research 2023 Annual Meeting, taking place from April 14-19, 2023 in Orlando, Florida.

• Tango Therapeutics Announces Limited Exposure to Silicon Valley Bank

  3/11/2023

  Tango Therapeutics, Inc. reported that it is aware of the current situation affecting Silicon Valley Bank, it is monitoring this situation closely and does not expect its exposure to SVB will require any change to its previously provided guidance that it has sufficient cash, cash equivalents and marketable securities to fund operations into 2025.

• Tango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

  3/6/2023

  Tango Therapeutics, Inc. today announced that, effective March 1, 2023, the Compensation Committee of Tango Therapeutics' Board of Directors granted non-qualified stock options to purchase an aggregate of 637,000 shares of its common stock and an aggregate of 106,250 restricted stock units (RSUs) to two new employees.

• Tango Therapeutics to Participate in Upcoming Investor Conferences - March 1, 2023

  3/1/2023

  Tango Therapeutics, Inc. today announced that Barbara Weber, M.D., President and Chief Executive Officer of Tango Therapeutics, is scheduled to participate in the following upcoming investor conferences in March.

• Tango Therapeutics to Participate in Upcoming Investor Conferences - February 2, 2023

  2/2/2023

  Tango Therapeutics , Inc. today announced that Barbara Weber, M.D., President and Chief Executive Officer of Tango Therapeutics, is scheduled to participate in the following upcoming investor conferences in February.

• Tango Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Highlights

  11/10/2022

  Tango Therapeutics, Inc., a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, reported its financial results for the third quarter ended September 30, 2022, and provided business highlights.

• Tango Therapeutics to Participate in Upcoming Investor Conferences

  11/7/2022

  Tango Therapeutics, Inc. today announced that Barbara Weber, M.D., President and Chief Executive Officer of Tango Therapeutics, is scheduled to participate in the following upcoming investor conferences in November.

• Tango Therapeutics Announces Presentation of Preclinical Data on PRMT5 Inhibitors TNG908 and TNG462 in Three Abstracts Accepted at 34th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics

  10/19/2022

  Tango Therapeutics, Inc. today announced that three abstracts have been selected for presentation as posters at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics, being held in Barcelona, Spain from October 26-28, 2022.

• Tango Therapeutics Announces Presentation of Preclinical Data on TNG260 and Discovery Platform Advances at SITC 37th Annual Meeting

  10/5/2022

  Tango Therapeutics, Inc. today announced that three abstracts have been selected for poster presentation at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting, November 8-12, 2022, in Boston, Massachusetts, and online.